Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
With
Otsuka Pharmaceutical Co., Ltd.
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who meet the following criteria will be included in the study:
aged 18 to 64 years
diagnosis of major depressive disorder during the study timeframe (ICD 9 codes 296.2, 296.3, 311)
evidence of at least 6 consecutive claims for traditional antidepressant therapy with a 30 day supply or at least 2 claims with a 90 day supply (consecutive defined as ≤15 days gap)
must be continually enrolled during the study timeframe and have both medical and pharmacy benefits
evidence of at least 4 consecutive claims for an atypical antipsychotic prescription with a 30 day supply or 2 claims with a 90 day supply (consecutive defined as ≤15 days gap)
evidence of antidepressant therapy for at least 60 consecutive days prior to the initiation of atypical antipsychotic
After at least a 60 day trial of traditional antidepressant medications, patient augments with an atypical antipsychotic medication for at least 4 months.
You may not be if
Patients are excluded if they:
have any claims for a diagnosis of schizophrenia, schizoaffective or bipolar disorder during the study period
have Electroconvulsive therapy (ECT) during the study period
new augmentation with mood stabilizers, L-thyroxine (T4), L-Thyronine (T3), buspirone, stimulant, or others during the post-period (table 1)
are pregnant during the study period
patients with Medicare or Medicaid
Clareo Health | Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
